亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung Cancer

杜瓦卢马布 医学 放射治疗 肺癌 肿瘤科 内科学 癌症 免疫疗法 外科 无容量
作者
Motoko Yoshikawa TACHIHARA,Kayoko Tsujino,Takeaki Ishihara,Hidetoshi Hayashi,Yuki Sato,Takayasu Kurata,Shunichi Sugawara,Yoshimasa Shiraishi,Shunsuke Teraoka,Koichi Azuma,Haruko Daga,Masafumi Yamaguchi,Takeshi Kodaira,Miyako Satouchi,Mototsugu Shimokawa,Nobuyuki Yamamoto,Kazuhiko Nakagawa,West Japan Oncology Group (WJOG)
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:9 (11): 1505-1505 被引量:79
标识
DOI:10.1001/jamaoncol.2023.3309
摘要

Importance: Administration of durvalumab after concurrent chemoradiotherapy is the standard treatment of unresectable, locally advanced non-small cell lung cancer (NSCLC); however, 20% to 30% of patients do not receive durvalumab because of adverse events (AEs) during concurrent chemoradiotherapy. In addition, radiotherapy and immunotherapy have a synergistic effect. Objective: To investigate the efficacy and safety of durvalumab immunotherapy plus concurrent radiotherapy followed by maintenance with durvalumab therapy for treatment of locally advanced NSCLC without chemotherapy. Design, Setting, and Participants: The multicenter, single-arm DOLPHIN (Phase II Study of Durvalumab [MEDI4736] Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients) nonrandomized controlled trial was performed by 12 institutions in Japan from September 13, 2019, to May 31, 2022. Participants in the primary registration phase included 74 patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, locally advanced NSCLC. The current analyses were conducted from June 1, 2022, to October 31, 2022. Interventions: Patients received radiotherapy (60 Gy) in combination with concurrent and maintenance durvalumab immunotherapy, 10 mg/kg every 2 weeks, for up to 1 year. Main Outcomes and Measures: The primary end point of the rate of 12-month progression-free survival (PFS), as assessed by an independent central review, was estimated using the Kaplan-Meier method and evaluated with 90% CIs calculated using the Greenwood formula. The key secondary end points were PFS, objective response rate, treatment completion rate, and AEs. Results: Data from 35 patients (median [range] age, 72 [44-83] years; 31 [88.6%] men) were included in the full analysis set of the evaluable population. The 12-month PFS rate was 72.1% (90% CI, 59.1%-85.1%), and the median PFS was 25.6 months (95% CI, 13.1 months to not estimable) at a median follow-up of 22.8 months (range, 4.3-31.8 months). Scheduled radiation therapy was completed in 97.1% of patients. The confirmed objective response rate was 90.9% (95% CI, 75.7%-98.1%), and the treatment completion rate was 57.6% (95% CI, 39.2%-74.5%). Among 34 patients evaluated in the safety analysis set, AEs of grade 3 or 4 occurred in 18 patients (52.9%), and of grade 5 in 2 patients (5.9%). Pneumonitis or radiation pneumonitis of any grade occurred in 23 patients (67.6%), and of grades 3 or 4 in 4 patients (11.8%). Conclusions and Relevance: Findings from this phase 2 nonrandomized controlled trial indicate that durvalumab immunotherapy combined with curative radiotherapy for patients with PD-L1-positive, unresectable, locally advanced NSCLC is a promising treatment with tolerable AEs and is appropriate as a study treatment for phase 3 clinical trials. Trial Registration: Japan Registry of Clinical Trials ID: jRCT2080224763.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
领导范儿的应助被佳佳采纳,获得10
6秒前
11秒前
动听阑悦完成签到 ,获得积分10
12秒前
淡淡的志泽完成签到,获得积分10
18秒前
18秒前
34秒前
Peiqi的应助被1874采纳,获得100
38秒前
farhad发布了新的文献求助10
39秒前
47秒前
petrichor发布了新的文献求助10
51秒前
syvshc的应助被宝石采纳,获得10
51秒前
大胆蛟凤完成签到,获得积分10
54秒前
1分钟前
may发布了新的文献求助10
1分钟前
1分钟前
五十二赫兹完成签到 ,获得积分10
1分钟前
1分钟前
大模型的应助被科研通管家采纳,获得10
1分钟前
1分钟前
高速公鹿发布了新的文献求助10
2分钟前
舒适刺猬完成签到 ,获得积分10
2分钟前
魏魏完成签到 ,获得积分10
2分钟前
旭旭完成签到,获得积分10
2分钟前
对白完成签到,获得积分10
2分钟前
ysh完成签到,获得积分10
3分钟前
林夕完成签到,获得积分10
3分钟前
3分钟前
和风完成签到 ,获得积分10
3分钟前
3分钟前
amiee发布了新的文献求助10
3分钟前
3分钟前
1874发布了新的文献求助30
3分钟前
3分钟前
穿肠酒发布了新的文献求助10
3分钟前
3分钟前
3分钟前
科研通AI6.3的应助被半亩月光采纳,获得10
4分钟前
魔幻初丹完成签到,获得积分10
4分钟前
4分钟前
佳佳发布了新的文献求助10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190117
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852170
捐赠科研通 7788359
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2559994
邀请新用户注册赠送积分活动 2482862